Global Information
회사소개 | 문의 | 비교리스트

신경면역 의약품의 개발

Neuroimmunology Drug Development

리서치사 GlobalData
발행일 2018년 12월 상품 코드 772768
페이지 정보 영문 76 Pages
가격
US $ 7,995 ₩ 9,448,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 15,990 ₩ 18,896,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 23,985 ₩ 28,345,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신경면역 의약품의 개발 Neuroimmunology Drug Development
발행일 : 2018년 12월 페이지 정보 : 영문 76 Pages

세계의 신경면역 의약품(Neuroimmunology Drug) 시장에서 신제품의 임상시험·개발 동향에 대해 분석했으며, 신경면역 제품의 정의·분류 방법과 공통 표적, 현재의 임상시험 진행 상황(질환별, 단계별, 지역별 등), 주요 기업 10개사의 개요와 주력 제품, 향후 기술·시장 동향에 대한 전문가 견해 등의 정보를 전해드립니다.

제1장 서론

제2장 주요 요약

제3장 신경면역 제품의 정의와 분류

제4장 신경면역학의 공통 목표 : 개요

  • 사이토카인
  • 림프구/분자와 활성화·융합작용의 관련성
  • 기타 공통 표적 : 신경면역 제품

제5장 출시된 신경면역 제품 평가

  • 증상과 분자 종류
  • 표적 종류

제6장 파이프라인상 신경면역 제품 평가

  • 제품 리스트 : 임상시험 단계(개발 단계)별
  • 제품 리스트 : 분자 종류별
  • 제품 리스트 : 표적별

제7장 특정 증상 분석 : 다발성 경화증(MS)

  • 질환 개요와 역학
  • 제품 개발 활동
  • 임상시험 최종 단계의 제품 프로파일

제8장 특정 증상 분석 : 알츠하이머병(AD)

  • 질환 개요와 역학
  • 제품 개발 활동
  • 임상시험 최종 단계의 제품 프로파일

제9장 신경면역 의약품의 임상시험 동향

  • 현재 진행중인 임상시험 : 활동 거점별 동향
  • 현재 진행중인 임상시험 : 상(단계)별, 후원 기업별 동향
  • 현재 진행중인 임상시험 : 분석 대상 증상별 동향
  • 병용요법 동향
  • 신경면역 시장 내부의 미충족 요구

제10장 부록

KSM 19.02.12

Among the different molecule types in neuroimmunology, mAbs and small molecules are the most common. This is primarily due to the specificity of the former and the ability of the latter to penetrate the BBB. However, the cost factor associated with mAbs-based therapy is seen as a hurdle for wider market acceptances.

Neuroimmunology is expected to be an area that will witness strong growth in the future due to a number of factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer's disease (AD) and Multiple Sclerosis (MS).

The most common targets adopted by pipeline drugs for MS include cytokines or cytokine receptors, as well as lymphocytes or molecule s associated with their activation or migration. The majority of pipeline drugs for AD are aimed at targeting the AB protein, the historical results of which have not been strong enough to be assigned as a breakthrough therapy.

The KOLs interviewed have highlighted the high cost of therapy associated with a mAb based therapy which is perceived as a hurdle for such drugs to be widely accepted in the market; this factor is expected to lead companies to develop more cost-efficient therapies based on alternate molecule types. They've also expressed the need for long-term safety and clinical data, as well as data to help them with decisions on sequential or combination therapies in neuroimmunology. These challenges are compounded when rare diseases are considered, primarily those related to patient recruitment.

The "Neuroimmunology Drug Development", report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology.

Scope:

This report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research -

  • Quotes from 10 key opinion leaders (3 US, 5 EU, 1 Japan, 1 China)
  • Summary of neuroimmunology product definitions and classifications
  • Overview of common targets and molecule types among current pipeline drugs, with focus on product development in AD and MS
  • Trends in ongoing clinical trials in neuroimmunology based on sponsor type, and phase of development
  • Call-outs of key information and details
  • Insight from GlobalData's specialist neurology analysts.

Reasons to buy:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the neuroimmunology market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the neuroimmunology market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Introduction

  • 1.1. Related Reports
  • 1.2. Upcoming Related Reports

2. Executive Summary

  • 2.1. Key Findings
  • 2.2. KOL Insights on Neuroimmunology Competitive Landscape

3. Neuroimmunology Product Definition and Classification

  • 3.1. GlobalData's Definition of Neuroimmunology Products

4. Overview of Common Targets in Neuroimmunology

  • 4.1. Cytokines
  • 4.2. Lymphocytes or Molecules Associated with their Activation or Migration
  • 4.3. Other Common Targets in Neuroimmunology

5. Assessment of Marketed Neuroimmunology Products

  • 5.1. Indications and Molecule Types
  • 5.2. Target Types

6. Assessment of Pipeline Neuroimmunology Products

  • 6.1. Products in Different Phases of Development
  • 6.2. Products by Different Molecule Types
  • 6.3. Products by Different Targets

7. Indication Specific Overview: Multiple Sclerosis

  • 7.1. Disease Overview and Epidemiology
  • 7.2. Product Development Activity
  • 7.3. Profiles of Products in Late - Stage Development

8. Indication Specific Overview: Alzheimer's Disease

  • 8.1. Disease Overview and Epidemiology
  • 8.2. Product Development Activity
  • 8.3. Profiles of Products in Late - Stage Development

9. Trends in Clinical Trials of Neuroimmunology Drugs

  • 9.1. Geographical Locations of Ongoing Clinical Trials
  • 9.2. Ongoing Clinical Trials by Different Phases and Sponsor Type
  • 9.3. Indications Being Evaluated in Ongoing Clinical Trials
  • 9.4. Combination Therapy Trends in Ongoing Clinical Trials
  • 9.5. Unmet Needs Within Neuroimmunology

10. Appendix

  • 10.1. Sources
  • 10.2. Primary Research
  • 10.3. About the Authors
  • 10.4. About GlobalData
  • 10.5. Contact Us
  • 10.6. Disclaimer
Back to Top
전화 문의
F A Q